ALTERITY THERAPEUTICS-ADR (ATHE) Stock Price, Quote, News and Overview
NASDAQ:ATHE - Nasdaq - US02155X2053 - ADR - Currency: USD
ATHE Quote, Performance and Key Statistics
ALTERITY THERAPEUTICS-ADR
NASDAQ:ATHE (2/5/2025, 8:00:00 PM)
After market: 3.93 -0.32 (-7.53%)4.25
-0.26 (-5.76%)
The current stock price of ATHE is 4.25 USD. In the past month the price increased by 13.94%. In the past year, price increased by 112.5%.
ATHE Latest News and Analysis
Wondering what's happening in today's after-hours session?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
What's Going On With Alterity Therapeutics Shares Thursday?
Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.
Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars
A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical...
ATHE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.83 | 336.82B | ||
| AMGN | AMGEN INC | 14.81 | 157.79B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 920.24 | 120.86B | ||
| GILD | GILEAD SCIENCES INC | 21.68 | 119.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.56 | 78.02B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.62B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.20B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 22.82B | ||
| BIIB | BIOGEN INC | 8.66 | 20.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.27 | 15.52B |
Related stock screener links
About ATHE
Company Profile
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 10 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Company Info
ALTERITY THERAPEUTICS-ADR
L 3 460 Bourke St
Melbourne VICTORIA VIC 3000 AU
CEO: David A. Stamler
Employees: 10
Company Website: https://alteritytherapeutics.com/
Investor Relations: http://pranabio.com/investors/
Phone: 61393494906
ATHE FAQ
What is the stock price of ATHE?
The current stock price of ATHE is 4.25 USD.
What is the symbol for ALTERITY THERAPEUTICS-ADR stock?
The exchange symbol of ALTERITY THERAPEUTICS-ADR is ATHE and it is listed on the Nasdaq exchange.
On which exchange is ATHE stock listed?
ATHE stock is listed on the Nasdaq exchange.
Is ATHE a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ATHE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ATHE.
Does ATHE stock pay dividends?
ATHE does not pay a dividend.
When does ATHE stock report earnings?
ATHE will report earnings on 2025-02-27.
What is the Price/Earnings (PE) ratio of ATHE?
ATHE does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.8).
What is the Short Interest ratio of ATHE stock?
The outstanding short interest for ATHE is 1.01% of its float.
ATHE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ATHE. When comparing the yearly performance of all stocks, ATHE is one of the better performing stocks in the market, outperforming 98.64% of all stocks.
ATHE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATHE. Both the profitability and financial health of ATHE have multiple concerns.
ATHE Financial Highlights
Over the last trailing twelve months ATHE reported a non-GAAP Earnings per Share(EPS) of -1.8. The EPS increased by 8.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -99.48% | ||
| ROE | -138.6% | ||
| Debt/Equity | 0 |
ATHE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 100% to ATHE. The Buy consensus is the average rating of analysts ratings from 1 analysts.